CLOSE

Subscribe to email alerts

ValoTx 05/08/2022

Valo Therapeutics Oy Shareholder Update 

On June 7th the German Regulatory Authority (PEI) granted clinical trial approval for our Phase 1 study to be conducted with PetiCRAd-1 at two sites in Germany. All regulatory and ethics related conditions have been met. 

Read the full Shareholder update here

Back to News

Related Articles

ValoTx

Valo Introduction Video

04/08/2022 Read more
ValoTx

Valo Immuno-Oncology Treatment

09/08/2022 Read more

CLOSE

Subscribe to email alerts